Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer.
AuthorsVon Pawel, J
Pujol, J L
Ranson, Malcolm R
AffiliationAsklepios Fachklinik, Gauting bei München, Munich, Germany.
MetadataShow full item record
AbstractPURPOSE: Topotecan, administered intravenously, is active in small-cell lung cancer (SCLC). In this study, the comparability of oral topotecan to IV topotecan was investigated. PATIENTS AND METHODS: Patients with SCLC that had relapsed 90 days or more after cessation of initial chemotherapy were randomized to receive either oral topotecan (Hycamtin) 2.3 mg/m(2)/d x 5 (52 patients) or IV topotecan 1.5 mg/m(2)/d x 5 (54 patients), every 21 days. RESULTS: Response rates in this phase II randomized study were 23% (12/52) in the oral topotecan arm and 15% (8/54) in the IV topotecan arm. All radiological responses were confirmed by an independent radiologist. Median survival was 32 weeks (oral) and 25 weeks (IV). Good symptom control, defined as sustained improvement or no deterioration, was evident in both treatment groups. Topotecan was generally well tolerated, with myelosuppression being the major toxicity. Grade 4 neutropenia occurred in 35.3% of patients on oral topotecan and in 67.3% of patients on IV topotecan, which was statistically significant (P =.001). Fever/infection more than or equal to grade 2 associated with grade 4 neutropenia, together with sepsis, occurred in only 5.1% of courses (oral) and 3.3% of courses (IV). Non-hematological toxicity consisted mainly of vomiting (oral: 36.5% of patients; IV: 31.5% of patients) and nausea (oral: 26.9% of patients; IV: 40.7% of patients). CONCLUSION: This study found oral topotecan to be similar in efficacy to IV topotecan in the treatment of patients with relapsed SCLC, sensitive to first-line chemotherapy, with less grade 4 neutropenia and greater convenience of administration.
CitationPhase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. 2001, 19 (6):1743-9 J. Clin. Oncol.
JournalJournal of Clinical Oncology
- A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
- Authors: Mok TS, Wong H, Zee B, Yu KH, Leung TW, Lee TW, Yim A, Chan AT, Yeo W, Chak K, Johnson P
- Issue date: 2002 Oct 1
- A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer.
- Authors: Quoix E, Breton JL, Gervais R, Wilson J, Schramel F, Cardenal F, Ross G, Preston A, Lymboura M, Mattson K
- Issue date: 2005 Aug
- Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.
- Authors: Eckardt JR, von Pawel J, Pujol JL, Papai Z, Quoix E, Ardizzoni A, Poulin R, Preston AJ, Dane G, Ross G
- Issue date: 2007 May 20
- Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen.
- Authors: Reck M, Groth G, Buchholz E, Goetz E, Gatzemeier U, Manegold C
- Issue date: 2005 Jun
- European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.
- Authors: Ardizzoni A, Manegold C, Debruyne C, Gaafar R, Buchholz E, Smit EF, Lianes P, ten Velde G, Bosquee L, Legrand C, Neumaier C, King K, Giuseppe giaccone European organization for research and treatment of cancer (EORTC) lung cancer group.
- Issue date: 2003 Jan